HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol).

Abstract
The prostate is a target organ of vitamin D receptor (VDR) agonists and represents an extra-renal site of 1,25-dihydroxyvitamin D(3) synthesis, but its capacity to respond to VDR agonists has, so far, been almost exclusively probed for the treatment of prostate cancer. We have analyzed the capacity of VDR agonists to treat benign prostatic hyperplasia (BPH), a complex syndrome characterized by a static component related to prostate overgrowth, a dynamic one responsible for urinary irritative symptoms, and an inflammatory component. Preclinical data demonstrate that VDR agonists, and notably BXL-628 (elocalcitol), reduce the static component of BPH by inhibiting the activity of intra-prostatic growth factors downstream of the androgen receptor, and the dynamic component by targeting bladder cells. In addition, BXL-628 inhibits production of proinflammatory cytokines and chemokines by human BPH cells. These data have led to a proof-of-concept clinical study that has successfully shown arrest of prostate growth in BPH patients treated with BXL-628, with excellent safety. We have documented the anti-inflammatory effects of BXL-628 also in animal models of autoimmune prostatitis, observing a significant reduction of intra-prostatic cell infiltrate following administration of this VDR agonist, at normocalcemic doses, in mice with already established disease. These data extend the potential use of VDR agonists to novel indications that represent important unmet medical needs, and provide a sound rationale for further clinical testing.
AuthorsLuciano Adorini, Giuseppe Penna, Susana Amuchastegui, Chiara Cossetti, Francesca Aquilano, Roberto Mariani, Benedetta Fibbi, Annamaria Morelli, Milan Uskokovic, Enrico Colli, Mario Maggi
JournalThe Journal of steroid biochemistry and molecular biology (J Steroid Biochem Mol Biol) Vol. 103 Issue 3-5 Pg. 689-93 (Mar 2007) ISSN: 0960-0760 [Print] England
PMID17241782 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • BXL628
  • Receptors, Calcitriol
  • Calcitriol
Topics
  • Animals
  • Calcitriol (analogs & derivatives, chemistry, pharmacology)
  • Dogs
  • Humans
  • Inflammation (drug therapy, metabolism, pathology)
  • Male
  • Middle Aged
  • Molecular Structure
  • Organ Size (drug effects)
  • Prostate (drug effects, growth & development, metabolism)
  • Prostatic Hyperplasia (drug therapy, metabolism, pathology)
  • Receptors, Calcitriol (agonists, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: